Breaking Down SG&A Expenses: Neurocrine Biosciences, Inc. vs Axsome Therapeutics, Inc.

A Decade of SG&A Evolution: Neurocrine Biosciences vs. Axsome Therapeutics

In the competitive landscape of biopharmaceuticals, understanding the financial dynamics of companies is crucial. Over the past decade, Neurocrine Biosciences, Inc. and Axsome Therapeutics, Inc. have shown distinct trajectories in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Neurocrine's SG&A expenses surged by nearly 500%, reflecting its aggressive expansion and operational scaling. In contrast, Axsome's expenses skyrocketed by over 23,000%, indicating a rapid growth phase, especially in recent years.

By 2023, Neurocrine's SG&A expenses were approximately 2.7 times higher than Axsome's, highlighting its more established market presence. This financial evolution underscores the strategic investments both companies are making to bolster their market positions. As the biopharma sector continues to evolve, these trends offer valuable insights into the operational strategies of leading players.